Cover ImageSALE
市場調查報告書

消化性潰瘍治療藥的全球市場:2017年∼2021年

Global Peptic Ulcer Drugs Market 2017-2021

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 310426
出版日期 內容資訊 英文 84 Pages
訂單完成後即時交付
價格
Back to Top
消化性潰瘍治療藥的全球市場:2017年∼2021年 Global Peptic Ulcer Drugs Market 2017-2021
出版日期: 2017年07月05日 內容資訊: 英文 84 Pages
簡介

全球消化性潰瘍治療藥市場,預計從2017年到2021年之間,以2.80%的年複合成長率擴大。

本報告提供全球消化性潰瘍治療藥市場相關調查,今後的成長預測,各地區趨勢,市場課題,機會及威脅,及主要供應商簡介彙整。

第1章 摘要整理

第2章 本報告的調查範圍

第3章 調查手法

第4章 簡介

  • 市場概要

第5章 消化性潰瘍:疾病概要

第6章 主要臨床實驗

第7章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 各類藥物的市場分類

  • 質子幫浦阻斷劑
  • 抗生素
  • 其他

第9章 地理區分

  • 南北美洲
  • 歐洲、中東、非洲地區
  • 亞太地區

第10章 決策架構

第11章 市場成長因素與課題

  • 市場成長因素
  • 市場課題

第12章 市場趨勢

第13章 業者情勢

  • 競爭模式

第14章 主要供應商分析

  • AstraZeneca
  • Daewoong Pharmaceuticals
  • Eisai
  • 武田藥品工業
  • 其他卓越供應商

第15章 附錄

  • 簡稱清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR13352

About Peptic Ulcer Drugs

A peptic ulcer is an open lesion, which develops on the mucosal lining of the stomach and the small intestine due to the caustic effect of the gastric acid and pepsin present in these organs. The general symptoms of a peptic ulcer include abdominal pain, nausea, vomiting, and bloated stomach. The specific symptom of peptic ulcer is the bleeding of the ulcer, which can be life-threatening. It is detected by bloody and sticky stools, often black in color. It is caused mainly by the Helicobacter pylori bacteria followed by the overuse of over-the-counter (OTC) non-steroidal anti-inflammatory drugs (NSAIDs) like naproxen, aspirin, and ibuprofen.

Technavio's analysts forecast the global peptic ulcer drugs market to grow at a CAGR of 2.80% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global peptic ulcer drugs market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Peptic Ulcer Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AstraZeneca,
  • Daewoong Pharmaceuticals,
  • Eisai,
  • Takeda Pharmaceutical

Other Prominent Vendors

  • GlaxoSmithKline
  • Pfizer

Market driver

  • Economics of treating ulcer
  • For a full, detailed list, view our report

Market challenge

  • Adverse effect of PPIs
  • For a full, detailed list, view our report

Market trend

  • Bismuth-based quadruple therapy
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Market outline

PART 05: Peptic ulcers: Disease overview

PART 06: Key clinical trials

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by drug class

  • PPIs
  • Antibiotics
  • Others

PART 09: Geographical segmentation

  • Peptic ulcer drugs market in Americas
  • Peptic ulcer drugs market in EMEA
  • Peptic ulcer drugs market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges

  • Market drivers
  • Market challenges

PART 12: Market trends

  • Bismuth-based quadruple therapy
  • Emergence of monotherapy
  • Recurrent H. pylori infections
  • Rise in awareness

PART 13: Vendor landscape

  • Competitive scenario

PART 14: Key vendor analysis

  • AstraZeneca
  • Daewoong Pharmaceuticals
  • Eisai
  • Takeda Pharmaceutical
  • Other prominent vendors

PART 15: Appendix

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Types of peptic ulcer
  • Exhibit 02: Global peptic ulcer drugs market: Pipeline landscape based on sponsors
  • Exhibit 03: Global peptic ulcer drugs market: Pipeline landscape
  • Exhibit 04: Global peptic ulcer drugs market: List of clinical trials and their aim/purpose
  • Exhibit 05: Snapshot of global peptic ulcer drugs market
  • Exhibit 06: Global peptic ulcer drugs market 2016-2021 ($ millions)
  • Exhibit 07: Opportunity analysis in global peptic ulcer drugs market
  • Exhibit 08: Five forces analysis
  • Exhibit 09: Segmentation of global peptic ulcer drugs market based on drug class 2016
  • Exhibit 10: Global peptic ulcer drugs market share based on drug class 2016
  • Exhibit 11: Global peptic ulcer PPIs drugs market 2016-2021 ($ millions)
  • Exhibit 12: Global peptic ulcer antibiotics drugs market 2016-2021 ($ millions)
  • Exhibit 13: Global peptic ulcer drugs market for others 2016-2021 ($ millions)
  • Exhibit 14: Segmentation of global peptic ulcer drugs market based on geography 2016 and 2021
  • Exhibit 15: Segmentation of global peptic ulcer drugs market revenue based on geography 2016-2021
  • Exhibit 16: Segmentation of global peptic ulcer drugs market based on geography 2016-2021 (%)
  • Exhibit 17: Market scenario in Americas
  • Exhibit 18: Peptic ulcer drugs market in Americas 2016-2021 ($ millions)
  • Exhibit 19: Market scenario in EMEA
  • Exhibit 20: Peptic ulcer drugs market in EMEA 2016-2021 ($ millions)
  • Exhibit 21: Market scenario in APAC
  • Exhibit 22: Peptic ulcer drugs market in APAC 2016-2021 ($ millions)
  • Exhibit 23: Age-related proportion of patients with duodenal and gastric ulcer
  • Exhibit 24: Some of the marketed combination products
  • Exhibit 25: Revenue erosion of Pariet after loss of exclusivity
  • Exhibit 26: Competitive structure analysis of global peptic ulcer drugs market 2016
  • Exhibit 27: AstraZeneca: Key highlights
  • Exhibit 28: AstraZeneca: Strength assessment
  • Exhibit 29: AstraZeneca: Strategy assessment
  • Exhibit 30: AstraZeneca: Opportunity assessment
  • Exhibit 31: Daewoong Pharmaceuticals: Key highlights
  • Exhibit 32: Daewoong Pharmaceuticals: Strength assessment
  • Exhibit 33: Daewoong Pharmaceuticals: Strategy assessment
  • Exhibit 34: Daewoong Pharmaceuticals: Opportunity assessment
  • Exhibit 35: Eisai: Key highlights
  • Exhibit 36: Eisai: Strength assessment
  • Exhibit 37: Eisai: Strategy assessment
  • Exhibit 38: Eisai: Opportunity assessment
  • Exhibit 39: Takeda Pharmaceutical: Key highlights
  • Exhibit 40: Takeda Pharmaceutical: Strength assessment
  • Exhibit 41: Takeda Pharmaceutical: Strategy assessment
  • Exhibit 42: Takeda Pharmaceutical: Opportunity assessment
Back to Top